Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- Cagrilintide and tirzepatide are different drug classes (amylin analog vs GLP-1/GIP dual agonist) with different mechanisms
- Tirzepatide produces greater mean weight loss in trials: ~22.5% (SURMOUNT-1) vs ~10% for cagrilintide monotherapy (Lau et al. 2021)
- Tirzepatide is FDA-approved (Mounjaro, Zepbound); cagrilintide is investigational
- The drugs may be more complementary than competitive; CagriSema combines amylin with GLP-1 rather than replacing one with the other
- FormBlends offers tirzepatide-based therapy through FDA-approved and 503A-compounded channels but does not offer cagrilintide
Direct answer
Cagrilintide and tirzepatide are different drug classes with different mechanisms. Tirzepatide is a GLP-1/GIP dual agonist that produces approximately 22.5% mean weight loss at 15 mg weekly in SURMOUNT-1. Cagrilintide is an amylin analog that produces approximately 10% mean weight loss at 2.4 mg weekly in phase 2 monotherapy. Tirzepatide is FDA-approved; cagrilintide is investigational. The two are not really substitutes; they activate different pathways and serve different roles. For pure weight loss as monotherapy, tirzepatide is the stronger and currently available option.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What each drug is, briefly
- Mechanism differences in detail
- Weight loss data side by side
- Side effects and tolerability
- Approval status and access
- The format and dosing comparison
- How they fit together: CagriSema as the bridge
- Cost comparison
- Patient profiles for each
- The contrary view: cagrilintide's role may grow
- Decision framework
- FAQ
- Sources
What each drug is, briefly
Tirzepatide is a synthetic peptide that activates both GLP-1 and GIP receptors. It is FDA-approved as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023). It is administered by subcutaneous injection once weekly. Mean weight loss in SURMOUNT-1 was approximately 22.5% at the 15 mg dose over 72 weeks.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. It activates amylin and calcitonin receptors. It is administered by subcutaneous injection once weekly. Cagrilintide is investigational and not FDA-approved as of May 2026. Mean weight loss in phase 2 monotherapy was approximately 10% at the 2.4 mg dose over 26 weeks.
The two drugs come from different companies, target different receptors, and have different positions in the development pipeline. They are not direct competitors in the same way that semaglutide and tirzepatide compete; cagrilintide more likely serves as a combination partner (CagriSema) than a standalone alternative to tirzepatide.
Mechanism differences in detail
The mechanism differences explain most of the efficacy and side effect differences.
| Feature | Tirzepatide | Cagrilintide |
|---|---|---|
| Drug class | GLP-1/GIP dual agonist (peptide) | Amylin analog (peptide) |
| Primary receptors | GLP-1 receptor + GIP receptor | Amylin receptor + calcitonin receptor |
| Insulin secretion | Enhanced (glucose-dependent) | Not directly affected |
| Glucagon | Suppressed | Suppressed post-meal |
| Gastric emptying | Slowed | Slowed |
| Central appetite | Hypothalamus + mesolimbic effects | Hypothalamus + area postrema |
| GIP-mediated effects | Yes (insulin, possibly adipose tissue) | No |
| Calcitonin-related effects | No | Possible (bone, calcium) |
The overlapping effect between the two drugs is slowed gastric emptying. Both produce this, contributing to satiety. The non-overlapping effects are where the drugs diverge:
- Tirzepatide's insulin secretion enhancement is significant for diabetes management and contributes to weight effects
- Tirzepatide's GIP component adds weight-loss-relevant effects that cagrilintide does not have
- Cagrilintide's calcitonin receptor activation is a different signaling profile that may have unique effects (some patients have asked about bone metabolism implications; data is limited)
The mechanism difference is the reason the drugs are studied in combination (CagriSema) rather than head-to-head. They activate different parts of the satiety and metabolism control system.
Weight loss data side by side
| Trial | Drug + Dose | Duration | Mean weight loss | Population |
|---|---|---|---|---|
| SURMOUNT-1 (Jastreboff 2022) | Tirzepatide 5 mg | 72 weeks | ~15% | Obesity without diabetes |
| SURMOUNT-1 | Tirzepatide 10 mg | 72 weeks | ~19.5% | Obesity without diabetes |
| SURMOUNT-1 | Tirzepatide 15 mg | 72 weeks | ~22.5% | Obesity without diabetes |
| Lau et al. 2021 | Cagrilintide 0.3 mg | 26 weeks | ~6% | Overweight/obesity |
| Lau et al. 2021 | Cagrilintide 1.2 mg | 26 weeks | ~7.4% | Overweight/obesity |
| Lau et al. 2021 | Cagrilintide 2.4 mg | 26 weeks | ~10.1% | Overweight/obesity |
| Lau et al. 2021 | Cagrilintide 4.5 mg | 26 weeks | ~10.8% | Overweight/obesity |
| REDEFINE-1 (2024) | CagriSema 2.4 + 2.4 | 68 weeks | ~22.7% | Obesity without diabetes |
Reading this data:
Tirzepatide monotherapy produces more weight loss than cagrilintide monotherapy. The gap is substantial (~22.5% vs ~10%) at the comparable top doses.
Cagrilintide monotherapy is in roughly the same weight loss range as liraglutide (Saxenda), the older GLP-1 daily injection. Both produce around 8-10% weight loss at top doses.
The CagriSema combination produces weight loss comparable to tirzepatide alone, suggesting cagrilintide's value is primarily as a combination partner with GLP-1, not as a standalone competitor to GLP-1/GIP dual agonists.
Trial duration differs (26 weeks for Lau et al., 72 weeks for SURMOUNT-1, 68 weeks for REDEFINE-1). Longer trials generally produce more total weight loss as patients continue to lose. Adjusting for duration, the cagrilintide monotherapy projection might extend to roughly 12-15% over 72 weeks, still below tirzepatide.
Side effects and tolerability
| Side effect | Tirzepatide (SURMOUNT-1) | Cagrilintide (Lau et al. 2021) |
|---|---|---|
| Nausea | ~24-33% | ~30-40% at higher doses |
| Vomiting | ~8-15% | ~10-20% |
| Diarrhea | ~19-23% | ~10-15% |
| Constipation | ~11-17% | Less common |
| Discontinuation for AEs | ~6-9% | ~5-10% |
| Injection site reactions | ~3-5% | ~5-10% |
The two drugs have generally similar GI side effect profiles, with possibly more nausea on cagrilintide and slightly more diarrhea on tirzepatide. The class warnings differ:
Tirzepatide warnings (per FDA labeling):
- Boxed warning: thyroid C-cell tumors based on rodent studies
- Pancreatitis
- Acute gallbladder disease
- Hypoglycemia with concurrent insulin or sulfonylurea
- Diabetic retinopathy progression in some patients
Cagrilintide warnings would only be finalized at FDA approval, which has not occurred. The pramlintide (Symlin) labeling, as the closest existing amylin analog, includes a boxed warning for severe hypoglycemia when combined with insulin. A similar warning would likely apply to cagrilintide.
Long-term safety data: tirzepatide has accumulated several years of post-marketing experience. Cagrilintide has limited long-term safety data, with the largest dataset coming from CagriSema phase 3 trials. The full safety profile will emerge only after potential approval and broader use.
Approval status and access
Tirzepatide:
- FDA-approved as Mounjaro (May 2022) for type 2 diabetes
- FDA-approved as Zepbound (November 2023) for chronic weight management
- Available through retail pharmacy with prescription
- Available through Lilly Direct self-pay program ($499-$599/month for some vial doses)
- Available through 503A compounding pharmacies (status varies with FDA shortage designation)
- Insurance coverage: variable, with some plans covering Mounjaro for diabetes but not Zepbound for obesity
Cagrilintide:
- Investigational, not FDA-approved as of May 2026
- Available only through authorized clinical trials
- Not available through standard pharmacy channels
- Not approved for 503A compounding
- Gray-market suppliers offer products labeled as cagrilintide; these are not legitimate
- Insurance does not cover
For a patient making practical decisions today, only tirzepatide is realistically accessible.
The format and dosing comparison
Both drugs are subcutaneous injections delivered weekly. The patient experience is similar:
| Feature | Tirzepatide | Cagrilintide |
|---|---|---|
| Route | Subcutaneous injection | Subcutaneous injection |
| Frequency | Weekly | Weekly |
| Storage | Refrigerated | Refrigerated |
| Format | Pre-filled pens or compounded vials | Pre-filled pens (trial use); not commercially available |
| Titration | 2.5 mg start, increase every 4 weeks to maintenance 5-15 mg | 0.3 mg start, increase every 2-4 weeks to 2.4 mg |
| Onset of effect | Days to weeks for appetite changes | Days to weeks for appetite changes |
| Travel logistics | Cold chain plus needles | Same |
The format comparison favors neither drug. Both have similar logistics. The choice between them, if both were available, would come down to mechanism preference and efficacy, not format.
How they fit together: CagriSema as the bridge
The drugs may be more complementary than competitive. Novo's CagriSema program demonstrates this.
CagriSema combines cagrilintide (2.4 mg) and semaglutide (2.4 mg) in a single weekly injection. The phase 3 REDEFINE-1 readout (December 2024) reported approximately 22.7% weight loss at 68 weeks, comparable to tirzepatide alone in SURMOUNT-1.
The mechanism logic: cagrilintide adds amylin signaling to GLP-1 signaling, producing complementary effects. The combination matches tirzepatide-level weight loss through a different mechanism (GLP-1 + amylin vs GLP-1 + GIP).
For patients, this means the practical comparison is:
- Tirzepatide alone: ~22.5% weight loss, FDA-approved, available now
- CagriSema: ~22.7% weight loss, investigational, possibly available 2026-2027 if approved
- Cagrilintide alone: ~10% weight loss, unlikely commercial path
Cagrilintide monotherapy is unlikely to be commercially successful as a standalone obesity drug given the much stronger options available. Its role is as a combination partner.
Cost comparison
Tirzepatide pricing:
- Brand Zepbound: ~$1,059/month list price
- Lilly Direct vial: $499-$599/month self-pay
- Brand Mounjaro: ~$1,069/month list price
- Compounded tirzepatide: $300-$500/month typical (subject to shortage status)
Cagrilintide pricing (speculative, not yet approved):
- Brand pricing if approved as monotherapy: uncertain, possibly $500-$900/month
- CagriSema brand pricing if approved: likely similar to or above Zepbound, $1,000-$1,300/month
- Compounded cagrilintide from gray-market: $100-$300/month, but not legitimate
The cost comparison favors tirzepatide for legitimate access. Compounded options are roughly equivalent on price. Gray-market cagrilintide is cheaper but not safe or legal.
Patient profiles for each
Tirzepatide is the practical choice for:
- Patients seeking maximum mean weight loss as monotherapy
- Patients with type 2 diabetes (Mounjaro indication)
- Patients with insurance coverage for Zepbound or Mounjaro
- Patients comfortable with current injectable peptide therapy
- Anyone seeking immediate, legitimate, FDA-approved treatment
Cagrilintide could theoretically fit:
- Patients enrolled in active clinical trials
- Patients with specific interest in amylin pathway physiology
- Patients who have failed multiple GLP-1 medications and want a different mechanism (this scenario is rare)
For most patients, the choice is not really between cagrilintide and tirzepatide. It is between tirzepatide (available now) and waiting for CagriSema (potentially available 2026-2027 if approved).
The contrary view: cagrilintide's role may grow
The bullish case for cagrilintide rests on a few specific scenarios.
Combination therapy expansion. If CagriSema approves and demonstrates real-world success, cagrilintide becomes essential as the amylin component of the most-effective Novo product. Cagrilintide volume scales with CagriSema commercial success.
Patient subgroups respond differently. Some patients respond better to amylin-pathway therapy than to GLP-1 alone. If subgroup analyses identify these patients, cagrilintide monotherapy could find a niche role.
Side effect tolerability. For patients who cannot tolerate GLP-1 side effects (specifically, those who tolerate amylin signaling better), cagrilintide alone or in non-GLP-1 combinations could be useful. Data is limited on this.
Future combinations beyond CagriSema. Cagrilintide could combine with other Novo molecules or with non-Novo drugs in research collaborations. The amylin component has commercial value beyond the current CagriSema design.
Cardiovascular outcomes. If cagrilintide demonstrates cardiovascular benefit similar to semaglutide's SELECT trial results, the indication could expand beyond weight management. Cardiovascular outcomes trials for cagrilintide would take years to complete.
None of these scenarios make cagrilintide a tirzepatide-level monotherapy contender. They reflect possible expanded roles within the obesity drug ecosystem.
Decision framework
If your goal is weight loss therapy now:
Choose tirzepatide (Zepbound or Mounjaro for diabetes patients). It is FDA-approved, well-characterized, and immediately available. Cagrilintide is not a competitive alternative outside clinical trials.
If you have not responded well to GLP-1 therapy and want to try a different mechanism:
Discuss with your clinician whether clinical trial enrollment for cagrilintide or CagriSema makes sense. Trials offer supervised access. Outside of trials, the practical options are dose optimization, behavioral interventions, or waiting for newer approved drugs.
If you are interested in combination therapy specifically:
Wait for CagriSema potential approval if Novo's program continues forward. Do not stack cagrilintide and tirzepatide on your own; the combination has not been studied and the safety profile is unknown.
If cost is the primary barrier:
503A-compounded tirzepatide may be cheaper than branded options. Verify FDA shortage status and your clinician's ability to use compounded medications. Gray-market cagrilintide is cheaper but not legitimate; do not pursue this path.
FAQ
Is cagrilintide better than tirzepatide?
Based on available data, tirzepatide produces more weight loss as monotherapy. SURMOUNT-1 reported approximately 22.5% mean weight loss at 15 mg tirzepatide. Lau et al. reported approximately 10% mean weight loss at 2.4 mg cagrilintide. The drugs target different mechanisms (GLP-1/GIP vs amylin), so they are not directly competitive. Cagrilintide is also not FDA-approved, while tirzepatide is. For pure weight loss, tirzepatide is the stronger option.
What is the difference between cagrilintide and tirzepatide?
Cagrilintide is an amylin analog that activates amylin and calcitonin receptors. Tirzepatide is a dual agonist that activates GLP-1 and GIP receptors. They are different drug classes with different mechanisms. Tirzepatide is FDA-approved (as Mounjaro for diabetes and Zepbound for obesity). Cagrilintide is investigational and not FDA-approved. Both are injected weekly. Tirzepatide produces more mean weight loss in trials.
Should I take cagrilintide or tirzepatide?
Tirzepatide is the only one available legally outside of clinical trials. Cagrilintide is investigational. For most patients, tirzepatide is the practical choice as of May 2026. If you are interested in amylin-pathway therapy specifically, ask your clinician about clinical trial participation or wait for potential CagriSema approval. Do not substitute cagrilintide for tirzepatide based on online recommendations.
Can cagrilintide replace tirzepatide?
Unlikely. Cagrilintide produces less mean weight loss than tirzepatide in available data (~10% vs ~22.5%). The two drugs target different mechanisms and may serve complementary roles rather than substitutes. The CagriSema combination (cagrilintide + semaglutide) approaches tirzepatide-level efficacy in REDEFINE-1, but cagrilintide alone does not.
Why is tirzepatide more effective than cagrilintide?
Tirzepatide activates two complementary receptor pathways (GLP-1 and GIP) that drive multiple weight-loss mechanisms (insulin secretion, gastric emptying, appetite suppression, plus GIP-specific metabolic effects). Cagrilintide activates the amylin pathway, which primarily affects gastric emptying and satiety signaling. The dual-receptor mechanism of tirzepatide engages more weight-loss-relevant biology than single-pathway amylin signaling.
Do cagrilintide and tirzepatide work the same way?
No. They use different mechanisms entirely. Tirzepatide mimics two gut hormones (GLP-1 and GIP), enhancing insulin secretion, slowing gastric emptying, and reducing appetite through central nervous system effects. Cagrilintide mimics amylin, the satiety hormone secreted alongside insulin. The overlapping effect is slowed gastric emptying. The non-overlapping effects (insulin secretion, GIP signaling, central appetite control) differ significantly.
Is cagrilintide safer than tirzepatide?
Both have GI-dominant side effects (nausea, vomiting, diarrhea) at roughly comparable rates. Tirzepatide has extensive post-marketing data since 2022. Cagrilintide has limited safety database because it is investigational. Tirzepatide carries class-wide warnings (thyroid C-cell tumors, pancreatitis, gallbladder events). Cagrilintide's full safety profile will only emerge with broader use. Saying one is 'safer' is not supported by the current data.
Sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022;387:205-216. (SURMOUNT-1)
- Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management. The Lancet. 2021;398:2160-2172.
- Enebo LB, Berthelsen KK, Kankam M, et al. CagriSema phase 2 results. The Lancet. 2021;397:1736-1748.
- Novo Nordisk. REDEFINE-1 Phase 3 results, press release. December 2024.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. 2023.
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. 2022.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction. JAMA. 2024;331:38-48. (SURMOUNT-4)
- Hay DL, Chen S, Lutz TA, et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacological Reviews. 2015;67(3):564-600.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes. NEJM. 2023;389:2221-2232. (SELECT)
- U.S. Food and Drug Administration. Symlin (pramlintide) Prescribing Information.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide. NEJM. 2021;384:989-1002. (STEP 1)
Footer disclaimers
Platform Disclaimer. FormBlends provides clinician-supervised weight management with FDA-approved and 503A-compounded tirzepatide and semaglutide. Cagrilintide is investigational and not part of our formulary. We have no commercial relationship with Novo Nordisk or Eli Lilly.
Compounded Medication Notice. Compounded tirzepatide referenced in this article is prepared by licensed 503A pharmacies under prescription, subject to FDA shortage status and applicable regulation. Compounded tirzepatide is not FDA-approved and not therapeutically interchangeable with branded Mounjaro or Zepbound. Cagrilintide is not eligible for the standard 503A compounding pathway.
Results Disclaimer. Trial weight loss percentages cited reflect averages from published clinical studies. Individual results vary substantially. Cross-trial comparisons between tirzepatide and cagrilintide are imperfect because of differences in trial design, patient populations, and duration.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Cagrilintide and CagriSema are development names for investigational compounds owned by Novo Nordisk A/S. Wegovy, Ozempic, Saxenda, and Symlin are registered trademarks of Novo Nordisk. FormBlends has no affiliation with Eli Lilly or Novo Nordisk.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →